The global nanomedicine market size was worth USD 138.9 billion in 2016 which is anticipated to grow at a CAGR of more than 9.8% during the forecast period. Factors such as technological advancements along with significant applications in the prophylaxis of acute and chronic diseases, prevention intervention, and early disease diagnosis are accountable for progress of this industry. Miniaturization of bigger chemicals and structures at nanometric scale enables the modernization in drug administration thus leading to growth in nanotechnology market for healthcare industry.
Advancements in nanorobotics due to the escalation in funding from the government bodies are accountable to persuade potential to the nanomedicine market. Moreover, nanorobotics engineering projects which are targeting only the cancer cells without affecting the contiguous tissues is expected to promote progress through to 2025.
Factors such as the capability of nanotechnology to assist in both therapeutic and diagnostics sector simultaneously are accountable for a large number of researches which are undergoing in this sector. Moreover, application of DNA origami in the healthcare is accountable for the projected CAGR.
Furthermore, pipeline products based on the nano-molecules and related technologies are expected to promote the progress over the forecast period. Other factors such as, presence of number of products in phase II trial of clinical development and personalized treatment option is also available which is accountable for the development of nanotechnology for health care in the coming years.
In 2016, the foremost share was accounted by therapeutics owing to the existence of various products such as drug delivery systems, devices, and drugs falling in this classification. Number of therapeutic drugs that can be delivered through nano methods is increasing with the inclination of pharmaceutical companies towards these research activities.
Nanotechnology is a promising technology which delivers drugs at the site of action with an enhanced cellular penetration and reduced toxicity. The aforementioned fact, is supportive for the estimated share of therapeutics segment. Moreover, development of innovative delivery products by using various kinds of nanoparticles is anticipated to boost the market growth.
Based on application, the segment incorporates cardiology, infectious diseases, oncology, and other applications. In 2016, oncology segment dominated with approximately 47% revenue share.
Rise in the R&D and funding activities in this segment is attributive for the larger share of this segment. Moreover, continuous increase in the incidence of oncology diseases is attributive for the development of nanotechnology based products for cancer eradication.
Cardiology is expected to witness fastest growth as a result of higher demand in the projected period due to several opportunities such as implants for tissue regeneration, nanostructured stents, and therapeutic nano-vectors.
Nanomolecule Type Insights
The capability of nanoparticles to get linked with the chemical moieties in different forms such as scaffolds aids in performing different functions. Moreover, application of nanoparticles for active targeting by linking it to cell receptor’s ligands is expected to drive progress potentially nanotechnology.
Metal and metal oxide is expected to witness substantial demand due to its widespread utilization in diagnostics. These nanoparticles enable diagnosis through the unique properties of different metals and metal oxides.
Dendrimers and the inorganic nanoparticles are also anticipated to grow at a potential rate in the coming years as consequence of research carried out in these segments. Furthermore, rising inclination of physicians towards nanodevices for monitoring and prognosis is anticipated to boost demand in the coming years.
The nanomedicine market was dominated by North America with over 42% of revenue share due to escalating partnerships between nanomedicine startups and enterprises. Moreover, assistance from government organizations along with higher R&D expenditure is accountable for the largest share of the province in this sector.
Asia Pacific is anticipated to witness fruitful growth owing to factors such as rising demand for prophylaxis of life-threatening diseases and increase in a number of research grants. The escalation in a number of venture capital financiers and rising international research associations are expected to promote the nanomedicine growth in this region.
Several vital players are functioning in this market such as Teva Pharmaceutical Industries Ltd, Nanosphere, Inc., Celegene Corporation, Ablynx NV, GE Healthcare, Arrowhead Research, and Combimatrix Corp. These players are engaged in attaining the U.S. FDA approvals in order to enhance their revenue share.
Rising penetration of the companies in diverse segments with respect to nanotechnology in order to replace the conventional options of treatment and diagnosis is anticipated to lead in growth in the coming years. Market entities are engaged in collaborations with research institution and academic organizations in order to carry out active research.
Product Outlook (Revenue, USD Billion; 2013 - 2025)
• Regenerative medicine
• In-vitro diagnostics
• In-vivo diagnostics
Application Outlook (Revenue, USD Billion; 2013 - 2025)
• Clinical Oncology
• Infectious diseases
• Clinical Cardiology
Nanomolecule Type Outlook (Revenue, USD Billion; 2013 - 2025)
• Metal & Metal Oxide Nanoparticles
• By Type
• Gold Nanoparticles
• Silver Nanoparticles
• Iron Oxide Nanoparticles
• Alumina Nanoparticles
• Gadolinium Oxide Nanoparticles
• By Application
• In-vivo Imaging
• Targeted Drug Delivery
• Proton Therapy
• In-vitro assays
• Cell & Phantom Imaging
• Polymers & polymer drug conjugates
• Hydrogel nanoparticles
• Inorganic nanoparticles
Regional Outlook (Revenue, USD Billion; 2013 - 2025)
• North America
• Asia Pacific
• Latin America
• Middle East and Africa (MEA)
• South Africa
Research Support Specialist, USA